ADRM1 and ovarian carcinoma: These candidate small molecular inhibitors of RPN13 (iRPN13) also rapidly produce toxic accumulations of high molecular weight (HMW) polyubiquitinated substrates as with VLX1570, and exhibit therapeutic activity in mice bearing liquid [28] or solid tumor models [29, 30], including of ovarian cancer [24].